Najat Khan

Insider Reports History

Location
Salt Lake City, UT
Signature
/s/ Kyle Nelson, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Najat Khan:

Company Role Class Num Shares Value Price $ Report Date Ownership
RECURSION PHARMACEUTICALS, INC. Chief R&D Commercial Officer, Director Class A Common Stock 611,135 $2,694,983 $4.41 22 Dec 2025 Direct
RECURSION PHARMACEUTICALS, INC. Chief R&D Commercial Officer, Director Stock Option (Right to Buy) 993,944 22 Dec 2025 Direct

Insider Reports Filed by Najat Khan

Symbol Company Period Transactions Value $ Form Type Role Filing Time
RXRX RECURSION PHARMACEUTICALS, INC. 22 Dec 2025 1 -$548,592 4 Chief R&D Commercial Officer, Director 29 Dec 2025, 17:24
RXRX RECURSION PHARMACEUTICALS, INC. 17 Nov 2025 1 -$72,798 4 Chief R&D Commercial Officer, Director 19 Nov 2025, 19:37
RXRX RECURSION PHARMACEUTICALS, INC. 05 Nov 2025 2 $0 4 Chief R&D Commercial Officer, Director 06 Nov 2025, 16:23
RXRX RECURSION PHARMACEUTICALS, INC. 15 Aug 2025 2 -$223,543 4 Chief R&D Commercial Officer, Director 19 Aug 2025, 18:22
RXRX RECURSION PHARMACEUTICALS, INC. 15 May 2025 1 -$16,133 4 Chief R&D Commercial Officer, Director 19 May 2025, 16:44
RXRX RECURSION PHARMACEUTICALS, INC. 03 Feb 2025 4 -$19,959 4 Chief R&D Commercial Officer, Director 05 Feb 2025, 16:50
RXRX RECURSION PHARMACEUTICALS, INC. 01 Aug 2024 2 $0 4 Chief R&D Commercial Officer, Director 05 Aug 2024, 17:12
RXRX RECURSION PHARMACEUTICALS, INC. 16 Apr 2024 0 $0 3 Director 25 Apr 2024, 17:08